News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2020
-
Mar 30, 2020
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 148KB] -
Mar 24, 2020
Genentech Announces FDA approval of Clinical Trial for Chugai’s Actemra for COVID-19 Pneumonia
[PDF 354KB] -
Mar 23, 2020
Chugai Files Patent Infringement Lawsuit against Fresenius Kabi in the U.S.
[PDF 108KB] -
Mar 19, 2020
Roche Announces the Initiation of a Clinical Study of Chugai’s Actemra for the Treatment of COVID-19
[PDF 188KB] -
Mar 17, 2020
Chugai Selected as 2019 Tokyo Sports Promotion Model Company
[PDF 191KB] -
Mar 13, 2020
Chugai Orgazanizes a Workshop on Multidisciplinary Team Care in Cambodia
- To provide advanced and sustainable patient-centric healthcare - [PDF 427KB] -
Feb 21, 2020
Chugai Obtains Approval for Additional Indication of Alecensa for Recurrent or Refractory ALK Fusion Gene-Positive Anaplastic Large Cell Lymphoma
[PDF 349KB] -
Feb 21, 2020
Chugai Obtains Approval for Additional Indication of Rozlytrek for ROS1 Fusion-Positive Non-Small Cell Lung Cancer
[PDF 208KB] -
Feb 21, 2020
Anti-CD20 Monoclonal Antibody “Rituxan®,” Approved for Additional Indication of Acquired Thrombotic Thrombocytopenic Purpura
[PDF 80KB] -
Feb 20, 2020
Results of Phase II Study with Chugai’s Nemolizumab for Prurigo Nodularis Published in the New England Journal of Medicine Online
[PDF 325KB] -
Feb 17, 2020
Chugai Receives Orphan Drug Designation for RG6042 in Huntington's Disease from the MHLW
[PDF 373KB] -
Feb 17, 2020
Changes to Marketing Arrangements of the SGLT2 Inhibitor Tofogliflozin Hydrate in Japan
[PDF 160KB] -
Feb 14, 2020
Chugai Files for Additional Indications of Tecentriq and Avastin for the Treatment of Unresectable Hepatocellular Carcinoma
[PDF 241KB] -
Feb 13, 2020
Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne® Liquid in the Third Stage of SCRUM-Japan
[PDF 168KB] -
Feb 13, 2020
Polatuzumab Vedotin Achieved Primary Endpoint in the Japanese Phase II study for Relapsed or Refractory Diffuse Large B-cell Lymphoma
[PDF 210KB] -
Feb 12, 2020
Chugai Wins Second Prize for the Second Consecutive Year in the 22nd NIKKEI Annual Report Awards
- First time to win both Nikkei and WICI Japan Awards for Integrated Reporting - [PDF 215KB] -
Feb 12, 2020
Chugai Joins the Consortium of Companies Promoting Anti-Smoking Efforts
[PDF 280KB] -
Feb 07, 2020
Chugai Supports National Cancer Center Japan for an Investigator-Initiated Clinical Study Based on Patient-Requested Therapy System
[PDF 195KB] -
Feb 07, 2020
Support for Control of Novel Coronavirus
[PDF 274KB] -
Feb 04, 2020
Chugai Supports Statement of Japan Climate Initiative and Recommendations of the Task Force on Climate-related Financial Disclosures
[PDF 194KB] -
Jan 30, 2020
Chugai Announces 2019 Full Year Results and Forecasts for 2020
[PDF 443KB] -
Jan 30, 2020
Notice of Distribution of Retained Earnings
[PDF 179KB] -
Jan 30, 2020
Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year
[PDF 129KB] -
Jan 30, 2020
Organizational and Personnel Changes
[PDF 427KB] -
Jan 30, 2020
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2019
[PDF 107KB] -
Jan 28, 2020
Notice Concerning Execution of Settlement Agreement on Arbitration against Chugai
[PDF 65KB] -
Jan 23, 2020
Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in People with Type 1 Spinal Muscular Atrophy (SMA)
[PDF 197KB] -
Jan 21, 2020
Notice of Stock Split and Partial Amendment to the Articles of Incorporation
[PDF 88KB] -
Jan 09, 2020
Chugai Announces Global Licensing Agreement with Verastem Oncology for RAF/MEK Inhibitor CKI27
[PDF 275KB]
